Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sylwia Grodecka-Gazdecka is active.

Publication


Featured researches published by Sylwia Grodecka-Gazdecka.


Pharmacological Reports | 2012

Study of ABCB1 polymorphism frequency in breast cancer patients from Poland

Błażej Rubiś; Hanna Hołysz; Wojciech Barczak; Robert Gryczka; Mariusz Łaciński; Paweł Jagielski; Anna Czernikiewicz; Anna Polrolniczak; Aneta Wojewoda; Katarzyna Perz; Paweł Białek; Karolina Morze; Natalia Lisiak; Przemysław M. Mrozikiewicz; Sylwia Grodecka-Gazdecka; Maria Rybczynska

BACKGROUND The accumulation of mutagenic substances in the human body may result in DNA metabolism disruption followed by carcinogenesis. As a consequence of mutations in the genes coding for transmembrane protein pumps, the intracellular concentration of xenobiotics may significantly increase. This, in turn, may provoke altered risk for cancer development. The gene known to be the most relevant in the transport of numerous compounds is ABCB1 (also known as MDR1). Numerous mutations and polymorphisms that affect the encoded proteins (PgP) function were identified in this gene. The aim of the study was to define the frequency of 2677G>A,T and 3435C>T polymorphisms in a population of Polish breast cancer patients and to estimate their contribution to cancer development. METHODS The polymorphism frequency analysis (209 patients vs. 202 control subjects) was performed either by allele-specific amplification (2677G>A,T) or by restriction fragment length polymorphism (RFLP) using the SAU3AI restriction enzyme (3435C>T) followed by verification with hybridization probe assays in a Real-Time system and sequencing. RESULTS In the control group the frequency of individual 2677 genotypes was: wild homozygous GG = 34%, heterozygous G/T or G/A = 52.5% and variant homozygous AA or TT = 13.5%, while the genotype frequency in the group of studied patients was 43.5, 44.5 and 12%, respectively. In the control group, the frequency of individual 3435 genotypes was: CC = 25.4%, CT = 50.2%, TT = 24.4%, while the genotype frequency in the group of studied patients was 23, 46 and 31%, respectively. CONCLUSION Thus, no significant differences in the studied polymorphism frequencies were observed. It is then suggested that the studied polymorphisms, although probably good candidates in other tissue cancer types, might not be good predictive factors in breast cancer risk or development in Caucasians.


Pathology & Oncology Research | 2008

The Determination of VEGF and MVD, among Patients with Primary Breast Cancer

Anna Thielemann; Zygmunt Kopczyński; Violetta Filas; Jan Bręborowicz; Sylwia Grodecka-Gazdecka; Aleksandra Baszczuk

The purpose of the study was to ascertain the value of assessment of vascular endothelial growth factor (VEGF) levels and microvessel density, and to search for correlations between them, in women with breast cancer. The assessment considered factors such as the stage of clinical disease advancement—according to International Union Against Cancer, the grade of histological malignancy, status of axillary lymph nodes and the size of the primary tumour. The concentration of VEGF was assessed in the plasma of 103 women with breast cancer, using an immunoenzymatic method (Quantikine test of R&D Systems). Assessment of microvessel density was performed using histopathological immunoperoxidase methods, using an anti-von Willebrand factor antibody (DAKO A/S). A statistically significant relationship was found between rising VEGF levels and microvessel density in women with breast cancer, when compared to values from a control group. A correlation was found between VEGF concentration and microvessel density (MVD) values. Statistically significant differences were found between VEGF levels of patients in stages I, II and III of clinical disease advancement. For MVD, differences were found only between stages I and III. A statistical relationship was also found between VEGF and MVD and tumour size. Similar results were found between VEGF concentrations in women with metastases to the axillary lymph nodes and cytokine levels in women with no metastases. The results of the study suggest that the degree of tumour vascularization and the concentration of VEGF may represent valuable indicators for the assessment of the angiogenic process in women with breast cancer.


Wspolczesna Onkologia-Contemporary Oncology | 2014

The clinical usefulness of assessing the concentration of cell adhesion molecules sVCAM-1 and sICAM-1 in the serum of women with primary breast cancer.

Anna Thielemann; Aleksandra Baszczuk; Zygmunt Kopczyński; Adrianna Nowak; Sylwia Grodecka-Gazdecka

Aim of the study Assessment of the concentrations of the soluble forms of the cell adhesion molecules sVCAM-1 and sICAM-1 in serum of female breast cancer patients. These concentrations were assessed in relation to factors such as: age, clinical stage of disease, histological grade of malignancy, the status of the local axillary lymph nodes, and the size of the primary tumour. Material and methods A total of 103 patients with primary breast cancer, aged 29 to 89 years, were investigated. The control group consisted of 40 healthy women. The concentration of sVCAM-1 and sICAM-1 was assessed using an enzyme-linked immunosorbent assay (ELISA). Results The results of the study suggest that the level of sVCAM-1 and sICAM-1 in the serum of women with breast cancer was significantly higher than that seen in the serum of healthy women. A relationship between the level of adhesion molecules and the stage of clinical disease advancement was discovered. There was a correlation between the increasing concentrations of sVCAM-1 and sICAM-1 and with the aggressiveness of the disease. Significant differences were also found in the group of women with metastases to the axillary lymph nodes and women with no metastasis. Similar correlations were found between sVCAM-1 and sICAM-1 levels and the size of primary tumour. Conclusions The results obtained suggest that the assessment of the soluble forms of sVCAM-1 and sICAM-1 may be useful indicators in the assessment of the clinical advancement of breast cancer.


International Journal of Biological Markers | 2012

Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.

Piotr Piotrowski; Margarita Lianeri; Blazej Rubis; Hanna Knuła; Maria Rybczynska; Sylwia Grodecka-Gazdecka; Paweł P. Jagodziński

Background Breast cancer is a multifactorial disease caused by complex interactions between genetic and environmental factors. Recently, a functional polymorphism, MDM2 285G>C (rs117039649), has been discovered. This polymorphism antagonizes the effect of the 309T>G (rs2279744) polymorphism on the same gene, resulting in decreased MDM2 transcription. Methods The MDM2 285G>C and 309T>G polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing analysis in women with breast cancer (n=468) and controls (n=550). Results The odds ratio (OR) for breast cancer patients with the MDM2 285C/C and 285G/C genotypes was 0.4768 (95% confidence interval [CI] 0.2906–0.7824; p=0.0033, pcorr=0.0066). We also found a significantly lower frequency of the MDM2 285C allele in patients with breast cancer than in controls: the OR for the C allele in patients with breast cancer was 0.4930 (95% CI=0.3059–0.7947, p=0.0031, pcorr=0.0062). The p value of the chi-square test for the trend observed for the MDM2 285G>C polymorphism was statistically significant (ptrend=0.0036). The statistical power of this study amounted to 85% for the G/C or C/C genotypes and 85% for the C allele. However, we did not observe significant differences between the distribution of MDM2 309T>G genotypes and alleles in patients with breast cancer and healthy controls. Conclusion In a sample of the Polish population, we observed that the MDM2 285C gene variant may be a significant protective factor against breast cancer.


Reports of Practical Oncology & Radiotherapy | 2006

Expression of selected markers in patients treated for breast cancer – based on our own data

Sylwia Grodecka-Gazdecka; Robert Gryczka; Mikołaj Musiał; Tomasz Graja

Summary Background Breast cancer patients’ long-term survival rate depends on many factors, such as the biological features of the tumour, stage of disease and mode of treatment. In most cases, in management of breast cancer combination therapy is used, according to indications. Qualification for adjuvant therapy is based on the assessment of several factors of established prognostic and predictive values. As a standard the patients age, primary tumour size, axillary lymph node involvement, cancer histological type, its malignancy grade and steroid receptor expression are considered. Aim Analysis of status of selected immunohistochemical markers in a set of consecutive patients undergoing surgery for breast cancer. Materials/Methods Samples from 623 patients were examined. Colour reaction was used for oestrogen (ER) and progesterone (PgR) receptors, P53 protein, cathepsin D and c-erbB-2. Overexpression of HER-2 protein was examined in 150 patients. Results The presence of oestrogen receptors in cell nuclei was detected in 431 (69.2%) patients, of progesterone receptors in 504 (80.2%), and ER+, PgR+ phenotype in 382 (61%) patients. Cathepsin D expression was observed in 438 (70.3%) subjects. In 176 (27.3%) patients P53 protein accumulation was observed. Oncoprotein c-erbB-2 overexpression was observed in 99 (15.9%) and overexpression of HER-2 receptor in 29 (19.8%) patients. Conclusions Nowadays oestrogen receptors are detected more frequently than in patients treated in the years 1980–1986. Detection rates of cathepsin D and P53 protein expression remain at comparable levels. The difference observed in detection rate of c-erbB-2 expression requires further analysis. Assessment of the correlation between expression of studied immunohistochemical markers and survival rate is necessary.


Reports of Practical Oncology & Radiotherapy | 2004

Examination of the breast in women treated for nodular thyroid disorders

Sylwia Grodecka-Gazdecka; Katarzyna Łącka; Tomasz Graja; Maciej Wawrzyniak

Summary The relationship between various mammary gland diseases and thyroid disorders has been the focus of interest at many research centres. What has been investigated are various genetic and hormonal underlying factors and conditions as well as the co-existence diseases of both organs. The aim Of the work was to examine the mammary gland in women treated for nodular thyroid disorders. Material and methods An analysis is presented comprising 269 patients with a diagnosed nodular thyroid disorders. The diagnosis of the breast included palpation, mammography, ultrasonography. In cases of suspected lesions additionally fine-needle aspiration and surgical biopsy were performed. Results Breast cancer, benign lesions and no pathology were found in 2%, 23% and 75% of all patients. Conclusions A significantly greater incidence of breast cancer was observed, which justifies especially careful diagnosis of the breast in patients with a well-diagnosed thyroid disorder.


Nowotwory | 2015

Systemowe uwarunkowania opóźnień w diagnostyce i leczeniu kobiet chorych na raka piersi w Polsce

Sylwia Grodecka-Gazdecka; Piotr Zaborek; Joanna Didkowska; Krystyna de Walden-Gałuszko; Paweł Handschuh; Tadeusz Pienkowski; Jacek Jassem

Wstep. Wyniki leczenia chorych na raka piersi zalezą w duzym stopniu od sprawnego przeprowadzenia procesu diagnostyczno-terapeutycznego. Szczegolnie istotny jest czas uplywający od początku choroby do rozpoczecia leczenia. Opoźnienie w podjeciu leczenia moze wynikac z przyczyn lezących po stronie pacjenta, lekarza lub systemu opieki zdrowotnej. Celem projektu bylo określenie przyczyn opoźnien w rozpoznawaniu i leczeniu chorych na raka piersi w Polsce. Poprzednio przedstawiliśmy przyczyny opoźnien wynikające z postaw pacjentek, natomiast w niniejszej pracy omowiono systemowe uwarunkowania opoźnien. Material i metody. Dane uzyskano z ankiety przeprowadzonej w grupie 1000 chorych na raka piersi, leczonych w 10 losowo wybranych polskich ośrodkach onkologicznych i szpitalach z oddzialami onkologicznymi. Czas i strukture procesu rozpoznawania raka piersi oceniono na podstawie pytan elektronicznego, interaktywnego kwestionariusza. Respondentki zaznaczaly, ktore spośrod 6 wydarzen przypadly im w udziale, oraz określaly czas, jaki uplynąl pomiedzy poszczegolnymi etapami. Wyniki. Średni czas opoźnienia wynikającego z systemowych uwarunkowan wyniosl 9,0 tygodni. Brak zachorowan na nowotwory w najblizszej rodzinie chorej związany byl z wydluzeniem opoźnienia o 2,1 tygodnia. W grupie chorych, ktore na pierwszą wizyte udaly sie do onkologa, opoźnienie bylo krotsze o 1,8 tygodnia w porownaniu z grupą, w ktorej pierwsza wizyta odbyla sie u lekarza innej specjalności. Chore w wieku powyzej 59 lat w porownaniu z mlodszymi chorymi oczekiwaly na rozpoczecie terapii o 1,5 tygodnia krocej. Średni czas oczekiwania w grupie chorych mieszkających w mieście powyzej 300 tys. mieszkancow byl o 1,3 tygodnia krotszy niz w grupie chorych z mniejszych miejscowości. Wieksza o 1 stopien nieufnośc w stosunku do systemu ochrony zdrowia i wynikow leczenia wplywala na wydluzenie opoźnienia o 0,8 tygodnia. Wiekszy o 1 punkt poziom wsparcia ze strony bliskich związany byl z krotszym o 0,6 tygodnia czasem do rozpoczecia leczenia. Wnioski. Dzialania na rzecz zmniejszenia systemowego opoźnienia w rozpoznawaniu i leczeniu chorych na raka piersi w Polsce powinny polegac na usprawnieniu i standaryzacji ściezek diagnostycznych, zwiekszaniu dostepności do badan mieszkankom mniejszych miejscowości, zmniejszaniu nieufności w stosunku do systemu opieki zdrowotnej oraz zwiekszaniu kompetencji i roli lekarzy rodzinnych w profilaktyce chorob nowotworowych. Priorytetem powinno byc szybkie utworzenie specjalistycznych ośrodkow diagnostyczno-leczniczych, zapewniających kompleksową opieke onkologiczną, ujednolicony sposob rozpoznawania nowotworu i wysoką jakośc leczenia.


Nowotwory | 2015

Prophylactic mastectomy should not be used in high risk breast cancer patients

Sylwia Grodecka-Gazdecka

Profi laktyczna mastektomia jest procedurą operacyjną, ktorej celem powinna byc eliminacja ryzyka zachorowania na raka piersi. Celowo uzywam sformulowania „powinna byc”, poniewaz jednym z argumentow na „nie” bedzie fakt, iz procedura ta jedynie zmniejsza, a nie znosi calkowicie powyzszego ryzyka.


Cancer Research | 2012

Abstract 5029: Upregulation of miRNA27, miRNA125a and 125b in ERalpha-negative breast cancers

Tomasz P. Lehmann; Konstanty Korski; Matthew Ibbs; Jan Bręborowicz; Sylwia Grodecka-Gazdecka; Robert Gryczka; Paweł P. Jagodziński

Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL MicroRNAs (miRNAs) are a major class of small endogenous RNA molecules that post-transcriptionally inhibit gene expression. Many miRNAs have been implicated in the human breast cancer. We show here the correlation between breast cancer types characterized upon histological and immunohistochemical analysis and miRNA expression in 22 Polish patients. The group was divided into three categories: ERalpha-negative / ERalpha-positive, HER2-negative / HER2-positive and lymph node -negative / lymph node -positive (N-/N+) cases. Surgically removed tumors were congealed in liquid nitrogen and subsequently small RNA was extracted. We investigated the level of miR-17-5p, miR-27, miR-125a, miR-125b and miR-206 using real-time PCR TaqMan probes. Let-7 miRNA and U6 RNA were used as reference genes. We observed upregulation of the subsequent suppressor miRNAs miR-27, miR-125a and 125b in ERalpha-negative tumors (p<0.05). Comparison of expression of miR-17-5p, miR-27, miR-125a, miR-125b and miR-206 in N- and N+ samples did not reveal any significant differences. We also observed a tendency to lower level of expression of all investigated miRNAs in HER2-positive patients in comparison with HER2-negative. We concluded that miR-27, miR-125a and miR-125b may play an important role in the regulation of ER-alpha expression in breast cancer cells. They could also be regarded as surrogate markers of ER-alpha -negativity. However, the small number of patients included to the study warrants further investigation in the larger cohort of breast cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5029. doi:1538-7445.AM2012-5029


Reports of Practical Oncology & Radiotherapy | 2006

Prognostic factors in melanoma

Witold Kycler; Sylwia Grodecka-Gazdecka; Jan Bręborowicz; Violetta Filas; Marek Teresiak

Summary Background There are clinical and pathological factors associated with the clinical course of melanoma. These parameters allow us to predict survival times and establish a course of treatment. Aim The aim of the study was to assess the significance of immunohistochemical markers in the progression of melanoma, and relate these findings to the influence of clinical and histological factors on survival time. Materials/Methods In this study, archival histological material obtained from 50 melanoma patients operated on in the Great Poland Cancer Centre between 1990–1995 was analysed. Using immunohistochemistry we detected the presence of markers known to be important in the diagnosis of melanoma, including: HMB-45, PCNA, Ki-67, MMP-2, CD44 and nm23. Following this, univariate logistic regression was performed and clinical, histopathological and immunohistochemical data of statistical significance were correlated with survival time using the Cox nonparametric proportional hazard regression model. Results The results suggested that the most important prognostic factors correlating with survival time were: the presence of nm23 antigen (p = 0.0342) and the thickness of the melanoma, as measured by the Breslow method in mm (p = 0.0191). According to the univariate analysis there were correlations between patient death or survival and the histological type, Superficial Spreading Melanoma Malignum (SSMM) (p = 0.0187), regional lymphatic metastases (p = 0.0030) and positive Ki-67 results (p = 0.0282). Conclusions Taken together, our results allowed us to conclude (a) that there was a correlation between survival time and nm23 antigen expression and the thickness of melanoma, as measured by the Breslow method in mm, (b) that there were correlations between patient survival or death and the histological type of Superficial Spreading Melanoma Malignum, regional lymphatic metastases and positive Ki-67, (c) that other parameters (age, gender, anatomical location of the melanoma, the presence of ulceration, lymphatic infiltration, the existence of satellites, and positive PCNA and MMP-2) showed no significant influence on survival.

Collaboration


Dive into the Sylwia Grodecka-Gazdecka's collaboration.

Top Co-Authors

Avatar

Tomasz Graja

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Witold Kycler

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jan Bręborowicz

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Robert Gryczka

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Violetta Filas

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Zygmunt Kopczyński

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Aleksandra Baszczuk

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Anna Thielemann

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Maria Rybczynska

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Mikołaj Musiał

Poznan University of Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge